---
title: "Breaking Barriers: Combining Cell Line Development Innovation with Improved Process Development Workflows to Streamline Path to FIH"
description: Learn how KBI Biopharma’s SUREtechnology Platform™, powered by Selexis®, combines refined project workflows to accelerate the development of complex biologics.
---

[Resources – KBI Biopharma ](https://www.kbibiopharma.com/our-resources)

# [Breaking Barriers: Combining Cell Line Development Innovation with Improved Process Development Workflows to Streamline Path to FIH](https://www.kbibiopharma.com/our-resources/breaking-barriers-combining-cell-line-development-innovation-with-improved-process-development-workflows-to-streamline-path-to-fih)

 Written by [KBI Biopharma](https://www.kbibiopharma.com/our-resources/author/kbi-biopharma) | Nov 13, 2024 4:06:04 PM

Learn how KBI Biopharma’s SUREtechnology Platform™, powered by Selexis®, combines refined project workflows to accelerate the development of complex biologics, from optimized cell line generation to rapid transitions to toxicology studies—all paving the way to First-in-Human trials.

 

 

### Overview

This webinar focuses on how KBI Biopharma's [SUREtechnology Platform™](https://www.kbibiopharma.com/capabilities/mammalian/suretechnology), powered by Selexis®, enables rapid advancement of new complex biologics from early development to first-in-human (FIH). Emphasizing both the speed and quality, the discussion will cover:

- Optimized Cell Line Development: How the integration of the SUREtechnology Platform™ accelerates the creation of high-performing, stable cell lines tailored for biologics production.
- Transposase and Versatility: Insights into the platform’s modular workflows and advanced transposase technology, which allows for highly efficient gene insertion, enabling increased clones performance consistency, further reducing cell line development bottlenecks.
- Streamlined Path to Toxicology Studies: A step-by-step breakdown of the streamlined process that minimizes time to reach preclinical toxicology milestones, emphasizing rapid transitions from cell line development to tox studies.
- Speed to FIH: How KBI Biopharma’s unique capabilities enable a significantly faster path to first-in-  
  human studies, ensuring customers can achieve clinical milestones with confidence.

### Presenters

 

### Let's Connect

Interested in learning more about KBI Biopharma? [Contact us](https://www.kbibiopharma.com/contact) today.

 

[View full post](https://www.kbibiopharma.com/our-resources/breaking-barriers-combining-cell-line-development-innovation-with-improved-process-development-workflows-to-streamline-path-to-fih)

```json
{
  "@context" : "http://schema.org",
  "@type" : "BlogPosting",
  "author" : {
    "@type" : "Person",
    "name" : "KBI Biopharma"
  },
  "dateModified" : "2026-03-26T16:02:56.421Z",
  "datePublished" : "2024-11-13T16:06:04Z",
  "headline" : "Breaking Barriers: Combining Cell Line Development Innovation with Improved Process Development Workflows to Streamline Path to FIH",
  "image" : {
    "@type" : "ImageObject",
    "height" : 628,
    "url" : "https://3803265.fs1.hubspotusercontent-na1.net/hubfs/3803265/KBI_OutsourcedPharma_BreakingBarriers.jpg",
    "width" : 1200
  },
  "mainEntityOfPage" : "https://www.kbibiopharma.com/our-resources/breaking-barriers-combining-cell-line-development-innovation-with-improved-process-development-workflows-to-streamline-path-to-fih",
  "publisher" : {
    "@type" : "Organization",
    "logo" : {
      "@type" : "ImageObject",
      "height" : 60.0,
      "url" : "https://f.hubspotusercontent10.net/hubfs/3803265/kbi-biopharma-3.png",
      "width" : 226.17188
    },
    "name" : "All Resources"
  }
}
```